Author:
Iula Rossella,De Novellis Danilo,Trastulli Fabio,Della Pepa Roberta,Fontana Raffaele,Carobene Angela,Di Perna Maria,D’Ambrosio Alessandro,Romano Martina,Leone Aldo,De Fazio Laura,Fiumarella Alfonso,Gaeta Giuseppe,Marafioti Violetta,Barbato Serafina,Palmieri Salvatore,Rocco Stefano,Serio Bianca,Califano Catello,Pane Fabrizio,Ferrara Felicetto,Giudice Valentina,Selleri Carmine,Catalano Lucio
Abstract
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hematology units of Campania region, Italy, who received a median of six treatment lines prior to belantamab-mafodotin. The overall response rate (ORR) was 40% (complete remission, CR, 11%; very good partial remission, VGPR, 11%; and partial remission, PR, 18%), with a median progression-free survival (PFS) and overall survival (OS) of 3 and 8 months, respectively. One of the most frequent drug-related adverse events was keratopathy observed in nine (32%) patients, leading to therapy discontinuation in only three (11%) of them. Moreover, 22 out of 28 total patients who were treated with at least two administrations achieved an ORR of 50% (CR, 14%; VGPR, 14%; and PR, 22%) with a median PFS and OS of 5 and 11 months, respectively. In conclusion, our multicentric study confirmed efficacy and safety of belantamab-mafodotin in triple-refractory MM patients even in the real-life setting.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献